Akoya Biosciences Inc

Akoya Biosciences, Inc. is a life sciences technology company delivering spatial biology solutions focused on transforming discovery and clinical research. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and treatment response. Akoya offers two distinct solutions, the CODEX and Phenoptics platforms, to serve the diverse needs of researchers across discovery, translational and clinical research. The company was founded by Garry Nolan, Yury Goltsev and Nikolay Samusik in 2015 and is headquartered in Marlborough, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Akoya Biosciences achieves record revenue, eyes strategic growth initiatives

Akoya Biosciences reported impressive financial performance and outlined strategic priorities for 2023, focusing on revenue growth and operational enhancements.
While facing challenges like anemic reagent revenue and increasing expenses, the company remains optimistic about its position for growth and market opportunities.
With a strong emphasis on partnerships, product innovation, and revenue diversification, Akoya is poised to leverage its strengths and navigate challenges for sustained success.

Akoya Biosciences reports record Q1 revenue and eyes sustained growth

Akoya Biosciences' Q1 performance reflects strong revenue growth and strategic focus on sustained high growth.
The company aims for cash flow positivity by 2025 through targeted spending and revenue growth.
Challenges include successful Fusion 2.0 upgrades and driving reagent growth, balanced with maintaining high performance.
Opportunities lie in upgrading customers, partnerships, and innovative solutions driving revenue growth.

Akoya Biosciences reports record Q2 revenue and strategic growth plans

Akoya Biosciences excelled in Q2 2023 with record revenue and system placements, showcasing strength in spatial biology solutions.
The company's focus on reagent revenue growth, system upgrades, and revenue guidance highlights a strategic path for future growth.
While facing challenges in gross margins and adoption methodologies, Akoya's investments and opportunities position it well for continued success.

Akoya Biosciences excels in Q3, eyes sustained growth and efficiency

Akoya Biosciences delivered a standout performance in Q3 2023, marked by record revenue and gross profit, supported by a robust install base and strategic initiatives.
The company's strengths lie in workflow efficiency enhancements, strong gross margins, and a clear growth strategy through services and partnerships.
Challenges include achieving cash flow positivity, sustaining margins, and driving adoption of new solutions, while opportunities abound in genomics, partnerships, and market expansion.
Overall, Akoya's focus on innovation, efficiency, and market positioning sets a solid foundation for continued growth and financial success.

Akoya Biosciences reports record-breaking revenue and strategic partnerships for growth

Akoya Biosciences delivered impressive financial performance in Q4 2023, showcasing revenue growth, cost management, and strategic investments. While facing challenges from macro pressures and underperformance in certain regions, the company remains focused on achieving cash flow breakeven by 2024. Akoya's strengths in partnerships and product enhancements position them well for continued growth and margin expansion.

Akoya Biosciences reports Q1 revenue decline but eyes growth opportunities

Akoya Biosciences faced revenue decline in Q1 due to weak instrument placements but saw growth in reagent and services revenue, aiming for breakeven by year-end.
The company updated its 2024 revenue outlook, expecting a measured recovery and sustained growth, with opportunities in partnerships and margin improvement initiatives.
Challenges include academic budget assumptions impacting revenue guidance and increasing outsourcing to CROs affecting reagent growth opportunities.
Despite challenges, Akoya's strengths lie in strong reagent revenue growth, strategic partnerships, and potential for achieving higher gross margins in the future.

Akoya Biosciences reports strong Q2 revenue growth and eyes market expansion

Akoya Biosciences demonstrated robust revenue growth in Q2 2024, driven by strong performance across instrument, reagent, and service segments.
While facing challenges in revenue guidance adjustments and delayed impact from NMPA approval in China, Akoya's strategic initiatives and product strengths offer promising opportunities for future growth.
Overall, Akoya's focus on financial goals, product innovation, and market expansion sets a positive trajectory for the company's performance and competitiveness in the biotech sector.

Akoya Biosciences reports Q3 revenue dip, focuses on strategic growth

Akoya Biosciences faced revenue challenges in Q3 2024 but showed operational improvements and strategic advancements.
The company is focused on enhancing efficiency, expanding product offerings, and leveraging partnerships for growth.
While navigating competitive pressures and cash flow concerns, Akoya Biosciences aims for sustainable profitability and market leadership.
Strategic initiatives, stable gross margins, and a strong leadership team position Akoya Biosciences for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Akoya Biosciences, Inc. (NASDAQ:AKYA ) Q3 2024 Earnings Conference Call November 14, 2024 5:00 PM ET Company Participants Priyam Shah - Head, IR Brian McKelligon - CEO Johnny Ek - CFO Conference Call Participants William Bonello - Craig-Hallum Mason Carrico - Stephens Kyle Mikson - Canaccord David Westenberg - Piper Tejas Savant - Morgan Stanley Subbu Nambi - Guggenheim Securities Mark Massaro - BTIG Operator Hello and thank you for standing by. Welcome to the Akoya Biosciences Third Quarter 2024 Earnings Conference Call.

Akoya Biosciences, Inc. (AKYA) Q3 2024 Earnings Call Transcript

Akoya Biosciences (AKYA) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.26 per share a year ago.

Akoya Biosciences (AKYA) Reports Q3 Loss, Lags Revenue Estimates

MARLBOROUGH, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the third quarter ending September 30, 2024.

Akoya Biosciences Reports Third Quarter 2024 Financial Results

MARLBOROUGH, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the third quarter of 2024 after the market closes on Thursday, November 14, 2024. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.

Akoya Bioscience to Report Third Quarter 2024 Financial Results on November 14, 2024

Consortium includes top universities, hospitals and industry partners, led by the Francis Crick Institute and The Royal Marsden NHS Foundation Trust

Akoya's Leading Spatial Proteomics Platforms Selected for Use by Ground-Breaking UK-Based MANIFEST Consortium to Revolutionize Cancer Immunotherapy

MARLBOROUGH, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), the Spatial Biology Company®, today announced Scott Mendel has been appointed as Chairman of its Board, effective October 2, 2024. Mr. Mendel succeeds Robert Shepler, founding Chairman, who will remain on Akoya's board. Mr. Mendel has served as a member of Akoya's board of directors since June 2021 and has over 30 years of financial and operational management experience.

Akoya Biosciences Announces Scott Mendel as Chairman of the Board of Directors

Akoya Biosciences, Inc. (NASDAQ:AKYA ) Q2 2024 Earnings Conference Call August 5, 2024 5:00 PM ET Corporate Participants Priyam Shah - Head, Investor Relations Brian McKelligon - Chief Executive Officer Johnny Ek - Chief Financial Officer Conference Call Participants William Bonello - Craig-Hallum Kyle Mikson - Canaccord Tejas Savant - Morgan Stanley David Westenberg - Piper Sandler Rachel Vatnsdal - JPMorgan Ricki Levitus - Guggenheim Vivian Bais - BTIG Tim Cheung - Capital One Mason Carrico - Stephens Operator Good day and thank you for standing by. Welcome to the Akoya Biosciences Second Quarter 2024 Earnings Conference Call.

Akoya Biosciences, Inc. (AKYA) Q2 2024 Earnings Call Transcript

Akoya Biosciences (AKYA) came out with a quarterly loss of $0.27 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.51 per share a year ago.

Akoya Biosciences (AKYA) Reports Q2 Loss, Misses Revenue Estimates

MARLBOROUGH, Mass., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the second quarter ending June 30, 2024.

Akoya Biosciences Reports Second Quarter 2024 Financial Results

MARLBOROUGH, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the second quarter of 2024 after the market closes on Monday, August 5, 2024. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.

Akoya Biosciences to Report Second Quarter 2024 Financial Results on August 5, 2024, and Participate at Two Upcoming Investor Conferences

Bionano Genomics

Cytek Biosciences

Danaher

Standard BioTools Inc

908 Devices

Olink Holding AB

Singular Genomics Systems

QIAGEN

Quantum-Si

Revvity Inc

Seer

Thermo Fisher Scientific

10X Genomics

Lab Instrument and Services providers in the healthcare industry can generate high recurring revenues. Many loss-making instrument makers in the industry may not provide meaningful returns and carry high risks. Cytek stands out as the best opportunity in the sector due to strong growth and manageable losses.

Lab Instrument Industry Update - New Commercial Entrants

Akoya Biosciences, Inc. (NASDAQ:AKYA ) Q1 2024 Earnings Conference Call May 13, 2024 5:00 PM ET Company Participants Priyam Shah - Head, IR Brian McKelligon - CEO Johnny Ek - CFO Conference Call Participants Kyle Mikson - Canaccord David Westenberg - Piper Sandler Mark Massaro - BTIG Tejas Savant - Morgan Stanley Subhalaxmi Nambi - Guggenheim Rachel Vatnsdal - JP Morgan Mason Carrico - Stephens Timothy Chiang - Capital One Operator Good day and thank you for standing by. Welcome to the Akoya Biosciences First Quarter 2024 Earnings Conference Call.

Akoya Biosciences, Inc. (AKYA) Q1 2024 Earnings Call Transcript

Akoya Biosciences (AKYA) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.49 per share a year ago.

Akoya Biosciences (AKYA) Reports Q1 Loss, Lags Revenue Estimates

MARLBOROUGH, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the first quarter ending March 31, 2024.

Akoya Biosciences Reports First Quarter 2024 Financial Results

Leveraging Akoya's market-leading PhenoImager HT platform and clinical development expertise with NeraCare's Immunoprint test and best-in-class clinical data, the partnership will focus on increasing access to life saving therapies for early-stage melanoma patients. Leveraging Akoya's market-leading PhenoImager HT platform and clinical development expertise with NeraCare's Immunoprint test and best-in-class clinical data, the partnership will focus on increasing access to life saving therapies for early-stage melanoma patients.

Akoya Biosciences and NeraCare Enter into an Exclusive Agreement to Enable Personalized Therapy Selection for Early-Stage Melanoma Patients

Akoya (AKYA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Akoya Biosciences (AKYA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

MARLBOROUGH, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company®, has opened its Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts to meet the accelerating demand for its spatial biology solutions and the increased utilization of the company's PhenoCycler®-Fusion and the PhenoImager® HT platforms.

Akoya Biosciences Opens Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts

MARLBOROUGH, Mass. and SHANGHAI, China, May 02, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA), The Spatial Biology Company®, and Shanghai KR Pharmtech, a leading company providing molecular diagnostic solutions in China, have jointly announced that KR-HT5, which Akoya Biosciences co-developed with Shanghai KR Pharmtech utilizing the PhenoImager HT technology as its foundation, has received premarket approval from China's National Medical Products Administration (NMPA) to support next generation pathology clinical workflows.

Akoya Biosciences and Shanghai KR Pharmtech Announce Chinese Regulatory Agency Premarket Approval for KR-HT5 in China to Support Next Generation Pathology Clinical Workflows

MARLBOROUGH, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the first quarter of 2024 after the market close on May 13th, 2024. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.

Akoya to Report First Quarter 2024 Financial Results on May 13th, 2024

MARLBOROUGH, Mass., April 05, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company®, today announced it will highlight case studies featuring its Spatial Biology 2.0 Solutions that enable unprecedented speed and scale for spatial biology studies at the American Association for Cancer Research (AACR) 2024 Annual Meeting in San Diego, April 5 to 10. In addition, the company will showcase new applications of its PhenoCode™ Signature Panels and preliminary data from the Thermo Fisher ViewRNA assays on Akoya's platforms.

Akoya Biosciences Showcases Spatial Biology 2.0 Solutions at AACR Annual Meeting with Case Studies Demonstrating Unprecedented Speed and Scale

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, announced today that it has been named as a qualified contract research organization (CRO) of Akoya Biosciences (Nasdaq: AKYA; “Akoya”). By combining Akoya's single-cell imaging solutions with BostonGene's unparalleled expertise in spatial proteomics sample processing and analysis, researchers will gain unprecedented access to the intricate landscape of cellular biology, paving.

Akoya Biosciences Names BostonGene as a Qualified CRO Service Provider

Akoya Biosciences, Inc. (NASDAQ:AKYA ) Q4 2023 Earnings Conference Call March 4, 2024 5:00 PM ET Company Participants Priyam Shah - Head, IR Brian McKelligon - CEO Johnny Ek - CFO Conference Call Participants Subbu Nambi - Guggenheim Kyle Mikson - Canaccord Tejas Savant - Morgan Stanley John Sourbeer - UBS Mark Massaro - BTIG Rachel Vatnsdal - JP Morgan Operator Good day and thank you for standing by. Welcome to the Akoya Biosciences Fourth Quarter 2023 Earnings Conference Call.

Akoya Biosciences, Inc. (AKYA) Q4 2023 Earnings Call Transcript

Akoya Biosciences (AKYA) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.50 per share a year ago.

Akoya Biosciences (AKYA) Reports Q4 Loss, Tops Revenue Estimates

Q4 2023 revenue $26.5 million and FY 2023 revenue $96.6 million Guiding FY 2024 revenue range $114.0-118.0 million and operating cash flow breakeven by YE 2024

Akoya Reports Record Revenue in the Fourth Quarter of 2023 and Provides Full Year 2024 Financial Outlook

MARLBOROUGH, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the fourth quarter and full year of 2023 after the market close on March 4th, 2024. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.

News for Akoya Biosciences Inc Stock (AKYA)